Lexicon Pharmaceuticals (LXRX) Equity Average (2011 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Equity Average data on file, last reported at $155.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $155.2 million, up 15.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $155.2 million (up 15.4% YoY), and the FY2025 annual result was $126.7 million, up 6.04% from the prior year.
• Equity Average improved to $155.2 million in Q1 2026 per LXRX's latest filing, from $113.8 million in the prior quarter.
• Over five years, Equity Average peaked at $264.4 million in Q2 2024 and troughed at $81.8 million in Q2 2022.
• A 5-year average of $142.6 million and a median of $130.6 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average soared 92.72% in 2024, then tumbled 52.26% in 2025.
• A 5-year view of Equity Average shows it stood at $130.6 million in 2022, then declined by 10.92% to $116.3 million in 2023, then jumped by 39.48% to $162.2 million in 2024, then decreased by 29.82% to $113.8 million in 2025, then soared by 36.32% to $155.2 million in 2026.
• Business Quant data shows LXRX's Equity Average at $155.2 million in Q1 2026, $113.8 million in Q4 2025, and $124.8 million in Q3 2025.